SPH ZHONGXI PHARM
GenericsSPH ZHONGXI PHARM is a generic drug manufacturer focused on Neurology.
SPH ZHONGXI PHARM's Key Drugs
SPH ZHONGXI PHARM's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
SPH ZHONGXI PHARM's Recent FDA Approvals
New NDA/BLA approvals for SPH ZHONGXI PHARM over the last two years — novel drugs only, excluding generics and label supplements.
SPH ZHONGXI PHARM's Therapeutic Areas
SPH ZHONGXI PHARM's approved drugs and pipeline span 1 therapeutic area, led by Neurology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SPH ZHONGXI PHARM's Top Competitors
SPH ZHONGXI PHARM's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SPH ZHONGXI PHARM Pipeline Snapshot
Active clinical trials for SPH ZHONGXI PHARM across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2025-04-16
- Latest
- 2025-11-03
- Applications
- 2